UPG-111

• Description :

  UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR) . UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system[1].

• CAS Number :

  [3090687-02-5]

• UNSPSC :

  12352209

• Target :

  Urotensin Receptor

• Related Pathways :

  GPCR/G Protein

• Field of Research :

  Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

• Smiles :

  O=C([C@@H](NC([C@H](C(C)(SSC[C@H](NC([C@@H](NC([C@@H](NC1=O)CCCN)=O)CC2=CC=C(C=C2)O)=O)C(N[C@H](C(O)=O)C(C)C)=O)C)NC([C@H](CC(O)=O)NC([C@H]3N(CCC3)C([C@H]([C@H](O)C)NC([C@@H](N)CCO)=O)=O)=O)=O)=O)CC4=CC=CC=C4)N[C@@H]1CC5=CNC6=CC=CC=C56

• Molecular Formula :

  C64H87N13O17S2

• Molecular Weight :

  1374.58

• References & Citations :

  [1]Merlino F, et al. Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators. J Med Chem. 2024 Aug 22;67 (16) :13879-13890.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported